89.59 USD
▲-0.46+4.16%
2026-08-03
市值
$12.62B
市盈率
—
EPS
-2.17
股息率
—
52 周区间
15.01 – 95.49
成交量
2.03M
Beta
1.26
目标价
106.09
52W 低 15.0152W 高 95.49
价格走势
公司简介
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ...